Latest revenue
$0
as of 2026-03-31
Latest net income
$-22.2M
as of 2026-03-31
Net margin
—
as of 2026-03-31
Community sentiment
Where do you think WHWK is heading?
Keep private notes on WHWK — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
WHWK vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $103.9M
- Enterprise value
- $79.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.89×
- Dividend yield
- 0.0%
- 52-wk high
- $5.50
- 52-wk low
- $1.57
- Beta
- —
- Shares out
- 24.6M
What this company does
Item 1. Business. Overview We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization. In December 2024, we entered into an intellectual property license agreement (the “WuXi License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a…
AI summary unavailable — showing raw filing excerpt
Generated from WHWK's filing dated 2026-03-12
Key risks
Item 1A. Risk Factors Investing in our common stock involves significant risks, some of which are described below. In evaluating our business, investors should carefully consider the following risk factors. These risks and uncertainties summarized above and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem immaterial may also impair our business operations. Please see page 2 of this Annual Report for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks actually occur, our business, financial…
AI summary unavailable — showing raw filing excerpt
Generated from WHWK's filing dated 2026-03-12
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.